App-Quantinova.ai

Long-term cognitive and motor decline across the spectrum of Lewy body disease.

Maria Camila Gonzalez - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Lewy body dementia

N/A

Longitudinal change in thalamic white matter macrostructure and volume in Parkinson’s disease depression

R. Bhome - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Maximising UPDRS information while minimising assessment time

G. Morinan - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Measures of Physical Activity in Parkinson’s Disease (MAPD)

J. Gilby - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Mortality of people with Parkinson’s disease in a large population-based cohort study. Time trends and relationship to disease progression.

O. Okunoye - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Neuroanatomical signatures of genetic risk for Parkinson’s Disease in healthy adults

S. Waters - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

NMDA Receptor Antibodies and Neuropsychiatric Symptoms in Parkinson’s Disease

L. Gibson - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Novel Cognitive Markers for Early Diagnosis and Monitoring of Progressive Supranuclear Palsy

M. Brzezicki - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Progressive supranuclear palsy

N/A

Novel quantitative measures with standardised graphical tasks to objectively assess subtle changes in fine motor skill in diagnosing and monitoring of Parkinson’s disease

R. Zietsma - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

OnabotulinumtoxinA treatment in patients with upper limb and lower limb spasticity from the ASPIRE study

G. Bavikatte - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

OnabotulinumtoxinA

Opicapone Analysis of Health Economic Costs in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study

A. Lees - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Opicapone in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study

A. Lees - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Parkinson’s Families Project: analysis of a large cohort of patients with early onset and familial Parkinson’s disease

C. Towns - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Parkinson’s disease and Post-COVID-19 syndrome

V. Leta - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Parkinson's disease

Levodopa

Peripheral neuromodulation for the treatment of bladder symptoms associated with Parkinson’s disease

M. Smith - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Physical activity and subjective perception of PD symptoms during COVID-19 lockdown: a clinical audit

V. Foster - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Movement disorders

N/A

PKG for the management of advance Parkinson’s Disease

S. Duja - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Rapid blinking as an early clinical marker of Parkinson’s disease

M. Francis - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Regional brain iron and gene expression variation in Parkinson’s disease

G. Thomas - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

SARS CoV2 in older patients with Parkinson’s.

M. Khwaja - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Filters

45280 Abstracts